Patient-reported outcomes with first-line nivolumab plus cabozantinib versus sunitinib in patients with advanced renal cell carcinoma treated in CheckMate 9ER: an open-label, randomised, phase 3 trial.
- DOI
- 10.1016/s1470-2045(21)00693-8
- Published
- 2022 Feb
- Container
- The Lancet. Oncology
- Publisher
- Not recorded
- Open access
- yes
Credibility signals
limited evidence Score 45/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.
Show all credibility signals
- cautionDOI registered: No matching Crossref record was present in this response.
- cautionDOI resolves: No matching Crossref record was present in this response.
- not scoredDirectory of Open Access Journals: No matching DOAJ record was present in this response. No allow-list match; this is not evidence of low credibility.
- not scoredMEDLINE indexed: Not checked or no result supplied; no credibility inference made.
- not scoredOpenAlex core source: Not checked or no result supplied; no credibility inference made.
- not scoredKnown publisher allow-list: Not checked or no result supplied; no credibility inference made.
- not scoredROR affiliation: Not checked or no result supplied; no credibility inference made.
- not scoredRetraction Watch retraction: No retraction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch expression of concern: No expression of concern notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch correction: No correction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch reinstatement: No reinstatement notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- supportingOpen access status: Normalized open-access status: open.
- not scoredPublication license: Not checked or no result supplied; no credibility inference made.
- not scoredPublication version: A publication version was supplied but is not scored.
- cautionMetadata completeness: 5 of 6 scored descriptive metadata groups are present; missing fields increase uncertainty.
Cite this work
BibTeX
@article{allodium:10.1016/s1470-2045-21-00693-8,
title = {Patient-reported outcomes with first-line nivolumab plus cabozantinib versus sunitinib in patients with advanced renal cell carcinoma treated in CheckMate 9ER: an open-label, randomised, phase 3 trial.},
author = {Cella D and Motzer RJ and Suarez C and Blum SI and Ejzykowicz F and Hamilton M and Wallace JF and Simsek B and Zhang J and Ivanescu C and Apolo AB and Choueiri TK},
year = {2022},
journal = {The Lancet. Oncology},
doi = {10.1016/s1470-2045(21)00693-8},
url = {https://doi.org/10.1016/s1470-2045(21)00693-8}
}RIS
TY - JOUR TI - Patient-reported outcomes with first-line nivolumab plus cabozantinib versus sunitinib in patients with advanced renal cell carcinoma treated in CheckMate 9ER: an open-label, randomised, phase 3 trial. AU - Cella D AU - Motzer RJ AU - Suarez C AU - Blum SI AU - Ejzykowicz F AU - Hamilton M AU - Wallace JF AU - Simsek B AU - Zhang J AU - Ivanescu C AU - Apolo AB AU - Choueiri TK PY - 2022 JO - The Lancet. Oncology DO - 10.1016/s1470-2045(21)00693-8 UR - https://doi.org/10.1016/s1470-2045(21)00693-8 ER -
APA
D, C., RJ, M., C, S., SI, B., F, E., M, H., JF, W., B, S., J, Z., C, I., AB, A., & TK, C. (2022). Patient-reported outcomes with first-line nivolumab plus cabozantinib versus sunitinib in patients with advanced renal cell carcinoma treated in CheckMate 9ER: an open-label, randomised, phase 3 trial.. The Lancet. Oncology. https://doi.org/10.1016/s1470-2045(21)00693-8
Source records
- pubmed · retrieved 2026-09-26T06:04:07.797Z